AustralianSuper Pty Ltd Acquires New Stake in LifeStance Health Group, Inc. $LFST

AustralianSuper Pty Ltd bought a new position in shares of LifeStance Health Group, Inc. (NASDAQ:LFST) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,101,010 shares of the company’s stock, valued at approximately $17,056,000. AustralianSuper Pty Ltd owned approximately 0.80% of LifeStance Health Group at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Royal Bank of Canada raised its stake in shares of LifeStance Health Group by 63.4% in the 1st quarter. Royal Bank of Canada now owns 70,248 shares of the company’s stock worth $468,000 after buying an additional 27,244 shares in the last quarter. AQR Capital Management LLC grew its holdings in LifeStance Health Group by 223.0% during the first quarter. AQR Capital Management LLC now owns 51,500 shares of the company’s stock worth $343,000 after acquiring an additional 35,554 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in LifeStance Health Group by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 142,950 shares of the company’s stock worth $952,000 after acquiring an additional 4,169 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in LifeStance Health Group by 1.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 615,652 shares of the company’s stock valued at $4,100,000 after acquiring an additional 11,331 shares during the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in shares of LifeStance Health Group during the 2nd quarter valued at about $70,000. 85.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LFST has been the topic of a number of research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday, December 29th. BTIG Research upped their price target on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday, December 12th. Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. UBS Group lifted their target price on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Finally, Wall Street Zen raised LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.83.

Insider Buying and Selling at LifeStance Health Group

In other news, insider Lisa K. Miller sold 57,240 shares of the company’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $6.43, for a total value of $368,053.20. Following the transaction, the insider owned 261,292 shares in the company, valued at $1,680,107.56. This represents a 17.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Bessler sold 119,942 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68. Following the sale, the director owned 1,318,983 shares of the company’s stock, valued at approximately $9,285,640.32. This represents a 8.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 327,326 shares of company stock valued at $2,259,317 in the last 90 days. 3.20% of the stock is currently owned by corporate insiders.

LifeStance Health Group Trading Down 0.4%

NASDAQ LFST opened at $7.07 on Friday. The firm’s 50 day moving average price is $6.96 and its two-hundred day moving average price is $5.78. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. LifeStance Health Group, Inc. has a twelve month low of $3.74 and a twelve month high of $8.30. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of -235.67 and a beta of 1.12.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.03. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The business had revenue of $363.81 million during the quarter, compared to analysts’ expectations of $355.06 million. During the same quarter last year, the firm posted ($0.02) earnings per share. LifeStance Health Group’s revenue was up 16.3% compared to the same quarter last year. Equities analysts anticipate that LifeStance Health Group, Inc. will post -0.18 EPS for the current year.

LifeStance Health Group Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.